GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Perhaps we should view severe hemophilia with inhibitors as the most important acquired form of clotting disorder.<

Agreed.

>My understanding is that this condition occurs in hemophilia patients who become immune to administration of standard treatment due to an immune mechanism.<

In most diseases, this predicament is described as having neutralizing antibodies. For some reason, the term inhibitors is preferred in hemophilia.

>Factor VII, being later in the extrinsic pathway, is able to bypass that defect. I suppose the reason Factor VII is not used all the time is mostly expense.<

The expense may be part of the reason, but it’s probably not the whole reason. It’s simply a “cleaner” solution to give a patient the coagulation factor he lacks (XIII or IX, as the case may be) if there are no neutralizing antibodies to render that approach unworkable.